Systemic Preventive and Detoxifying Efficacy of Phenolics and Flavonoids Against Carcinogenesis: A Comprehensive Analysis of the Transition from Cellular Protection to Systemic Metabolic Resilience: Systemic Preventive and Detoxifying Efficacy of Phenolics and Flavonoids Against Carcinogenesis

AlaaEddeen M. Seufi; Mona S.  Azab; Hanan T.  Hamza; Sherifa H.  Ahmed; Shayma  Mahmoud; Mohamed Hamza; Mossad A.  Salama; Fatma H. Galal

Authors

AlaaEddeen M. Seufi Cairo and Jouf Universities
Mona S. Azab Biology Department, College of Science, Jouf University, Aljouf, Sakaka, Saudi Arabia; Zoology Department, Faculty of Science, Benha University, Benha, Egypt.
Hanan T. Hamza Biology Department, College of Science, Jouf University, Aljouf, Sakaka, Saudi Arabia; Department of Zoology, Faculty of Science (Girls), Al-Azhar University, Nasr City, Cairo, Egypt.
Sherifa H. Ahmed Biology Department, College of Science, Jouf University, Aljouf, Sakaka, Saudi Arabia; Zoology Department, Faculty of Science, Port Said University, Port Said, Egypt.
Shayma Mahmoud Zoology Department, Faculty of Science, Menoufia University, Menoufia, Egypt.
Mohamed Hamza Biology Department, College of Science, Jouf University, Aljouf, Sakaka, Saudi Arabia.
Mossad A. Salama Department of Mathematics, College of Science, Jouf University, Aljouf, Sakaka, Saudi Arabia.
Fatma H. Galal Biology Department, College of Science, Jouf University, Aljouf, Sakaka, Saudi Arabia, and Entomology Department, Faculty of Science, Cairo University, Giza, Egypt.

Keywords:

Hepatocellular Carcinoma, Flavonoids, Phenolics, Nrf2-ARE Pathway, Phase II Detoxification, Nrf2 Paradox, Metabolic Resilience, Tumor Microenvironment, Nanocarrier Delivery

Abstract

Hepatocellular carcinoma (HCC) remains a formidable global health challenge, characterized by high mortality and strong links to chronic liver injury, metabolic dysfunction-associated steatotic liver disease (MASLD), and cirrhosis. Conventional therapeutic modalities show limited efficacy in advanced disease stages, highlighting an urgent need for effective chemopreventive and protective strategies. Dietary phenolics and flavonoids—secondary plant metabolites defined by their characteristic C6-C3-C6 phenylpropanoid scaffolds—have emerged as powerful bio-modulators capable of shifting cellular dynamics from localized antioxidant protection to systemic metabolic resilience. This review comprehensively synthesizes the multi-tiered mechanisms through which phenolic compounds exert anti-carcinogenic and detoxifying effects, with a particular focus on the transition from chronic inflammation to malignancy. Mechanistically, these compounds disrupt the pathogenic pro-inflammatory triad (NF-κB, STAT3, and COX-2), trigger apoptotic cascades (Bax/Bcl-2, caspases), and restore autophagic flux (AMPK/mTORC1) to eliminate damaged cellular components. At the core of their detoxifying potential is the activation of the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)-Antioxidant Response Element (ARE) axis. Activation of Nrf2 upregulates Phase II biotransformation and antioxidant enzymes (GSTs, NQO1, HO-1, GCL), establishing a "metabolic shield" that neutralizes and excretes electrophilic carcinogens while reinforcing cellular glutathione (GSH) pools. Furthermore, we address the dual role of Nrf2—the "Nrf2 paradox"—wherein transient activation confers chemoprevention in normal tissue, whereas constitutive hyperactivation drives chemoresistance and metabolic survival in established tumors. To bridge preclinical findings with clinical applications, we explore advanced delivery technologies (e.g., liposomes, nano-emulsions) that overcome poor phenolic bioavailability, alongside biosynthetic microbial chassis engineering and personalized, biomarker-driven supplementation.

References

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71: 209-249. https://doi.org/10.3322/caac.21660

Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., Finn, R.S. (2021). Hepatocellular carcinoma. Nature Reviews Disease Primers, 7(1): 6. https://doi.org/10.1038/s41572-020-00240-3

Villanueva, A. (2019). Hepatocellular Carcinoma. New England Journal of Medicine, 380(15): 1450-1462. https://doi.org/10.1056/NEJMra1713263

Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 74(3), 229–263. https://doi.org/10.3322/caac.21834

Lopes, S. R., Martins, C., Santos, I. C., Teixeira, M., Gamito, É., & Alves, A. L. (2024). Colorectal cancer screening: A review of current knowledge and progress in research. World journal of gastrointestinal oncology, 16(4), 1119–1133. https://doi.org/10.4251/wjgo.v16.i4.1119

Kim, H. S., El-Serag, H. B. (2019). The Epidemiology of Hepatocellular Carcinoma in the USA. Current gastroenterology reports, 21(4), 17. https://doi.org/10.1007/s11894-019-0681-x

El‐Serag, H. B., Kanwal, F. (2014). Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?. Hepatology, 60(5), 1767-1775. https://doi.org/10.1002/hep.27222

Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore, Md.), 77(4), 1335–1347. https://doi.org/10.1097/HEP.0000000000000004

Lin, W.C., Lin, Y.S., Chang, C.W., Chang, C.W., Wang, T.E., Wang, H-Y., Chen, M-J. (2020). Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma. PLOS ONE 15(5): e0233212. https://doi.org/10.1371/journal.pone.0233212

Choi, S., Kim, B. K., Yon, D. K., Lee, S. W., Lee, H. G., Chang, H. H., Park, S., Koyanagi, A., Jacob, L., Dragioti, E., Radua, J., Shin, J. I., Kim, S. U., & Smith, L. (2023). Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study. Clinical and molecular hepatology, 29(2), 433–452. https://doi.org/10.3350/cmh.2022.0316

Kopustinskiene, D. M., Jakstas, V., Savickas, A., & Bernatoniene, J. (2020). Flavonoids as Anticancer Agents. Nutrients, 12(2), 457. https://doi.org/10.3390/nu12020457

Stachelska, M. A., Karpiński, P., Kruszewski, B. (2025). A Comprehensive Review of Biological Properties of Flavonoids and Their Role in the Prevention of Metabolic, Cancer and Neurodegenerative Diseases. Applied Sciences, 15(19), 10840. https://doi.org/10.3390/app151910840

Bakrim, S., El Omari, N., El Hachlafi, N., Bakri, Y., Lee, L. H., Bouyahya, A. (2022). Dietary Phenolic Compounds as Anticancer Natural Drugs: Recent Update on Molecular Mechanisms and Clinical Trials. Foods (Basel, Switzerland), 11(21), 3323. https://doi.org/10.3390/foods11213323

Huang, W., Zhong, Y., Gao, B., Zheng, B., Liu, Y. (2023). Nrf2-mediated therapeutic effects of dietary flavones in different diseases. Frontiers in pharmacology, 14, 1240433. https://doi.org/10.3389/fphar.2023.1240433

Suraweera, T.L., Rupasinghe, H.P.V., Dellaire, G., Xu, Z. (2020). Regulation of Nrf2/ARE Pathway by Dietary Flavonoids: A Friend or Foe for Cancer Management?. Antioxidants (Basel, Switzerland), 9(10), 973. https://doi.org/10.3390/antiox9100973

Gelerstein-Claro, S., Méndez-Valdés, G., Rodrigo, R. (2025). Effects of the Pharmacological Modulation of NRF2 in Cancer Progression. Medicina, 61(12), 2224. https://doi.org/10.3390/medicina61122224

Zhang, J., Xu, H. X., Zhu, J. Q., Dou, Y. X., Xian, Y. F., & Lin, Z. X. (2023). Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment. International journal of biological sciences, 19(10), 3029–3041. https://doi.org/10.7150/ijbs.82401

Basli, A., Belkacem, N., Amrani, I. (2017). Health Benefits of Phenolic Compounds Against Cancers. In Phenolic Compounds- Biological Activity. InTechOpen. https://doi.org/10.5772/67232

Pyo, Y., Kwon, K. H., Jung, Y. J. (2024). Anticancer Potential of Flavonoids: Their Role in Cancer Prevention and Health Benefits. Foods (Basel, Switzerland), 13(14), 2253. https://doi.org/10.3390/foods13142253

Sharifi-Rad, J., Seidel, V., Izabela, M., Monserrat-Mequida, M., Sureda, A., Ormazabal, V., Zuniga, F. A., Mangalpady, S. S., Pezzani, R., Ydyrys, A., Tussupbekova, G., Martorell, M., Calina, D., Cho, W. C. (2023). Phenolic compounds as Nrf2 inhibitors: potential applications in cancer therapy. Cell communication and signaling: CCS, 21(1), 89. https://doi.org/10.1186/s12964-023-01109-0

Seufi, A.M., Ibrahim, S.S., Elmaghraby, T.K., Hafez, E.E. (2009). Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant/antioxidant activity: molecular and histological evidences. Journal of experimental & clinical cancer research : CR, 28(1), 80. https://doi.org/10.1186/1756-9966-28-80

Alhaithloul, H.A.S., Galal, F.H., Seufi, A.M. (2021). Effect of extreme temperature changes on phenolic, flavonoid contents and antioxidant activity of tomato seedlings (Solanum lycopersicum L.). PeerJ, 9, e11193. https://doi.org/10.7717/peerj.11193

Seufi, A.M., Mohammed, H.A., Moussa, F.I., El-Din, A.A.S., El-Saadani, M., Taha, T.H., Hafez, E.E. (2019). Protective Effects of the Aqueous Extract of Black Mulberry Leaves, Morus nigra, on Chlorpyrifos Toxicity in Male Albino Rats. Jordan Journal of Biological Sciences, 12(4), 385- 393.‏

Shang, F., Qu, Y., Wang, Z., Dong, L., Li, A., Zhang, D., Gong, S., Gao, Y., Bai, Q., Ming, L., Shao, L. (2026). Activation of Nrf2 with natural flavonoids and mesenchymal stromal/stem cells: mechanisms and therapeutic potential for inflammatory diseases. Stem cell research & therapy, 17(1), 122. https://doi.org/10.1186/s13287-026-04925-6

Lin, L., Wu, Q., Lu, F., Lei, J., Zhou, Y., Liu, Y., Zhu, N., Yu, Y., Ning, Z., She, T., Hu, M. (2023). Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers. Frontiers in oncology, 13, 1184079. https://doi.org/10.3389/fonc.2023.1184079

Sharma, R., Majee, C., Mazumder, R., Padhi, S., Khan, F., Pal, R.S. (2024). Insight into the Regulation of Nrf2/Keap 1 Pathway by Flavonoids as an Approach for Treatment of Liver Diseases: A Review. Indian J of Pharmaceutical Education and Research, 58(1s):s40-s57. https://www.ijper.org

Tenreiro, S., Falcão, A.S., Bender, N., Bernatova, I., Berry, A., Cuadrado, A., Eppenberger, P., Giona, L., Grochot-Przeczek, A., Heiss, E., Jakubowska, M., Long, P.F., Makhro, A., Masoodi, M., Morgenstern, C., Saso, L., Seabra, M.C., Sznarkowska, A., Sykiotis, G., Trougakos, I.P. (2026). NRF2 as a guardian of health: from an ancient survival pathway to a modern therapeutic target. Redox Biology, 94, 104217. https://doi.org/10.1016/j.redox.2026.104217

Pandey, P., Lakhanpal, S., Mahmood, D., Kang, H. N., Kim, B., Kang, S., Choi, J., Choi, M., Pandey, S., Bhat, M., Sharma, S., Khan, F., Park, M. N., Kim, B. (2025). An updated review summarizing the anticancer potential of flavonoids via targeting NF-kB pathway. Frontiers in pharmacology, 15, 1513422. https://doi.org/10.3389/fphar.2024.1513422

Tang, S., Wang, B., Liu, X., Xi, W., Yue, Y., Tan, X., Bai, J., Huang, L. (2024). Structural insights and biological activities of flavonoids: Implications for novel applications. Food Frontiers, 6: 218–247. https://doi.org/10.1002/fft2.494

Mendonca, P., Soliman, K.F.A. (2020). Flavonoids activation of the transcription factor Nrf2 as a hypothesis approach for the prevention and modulation of SARS-CoV-2 infection severity. Antioxidants, 9(8), 659. https://doi.org/10.3390/antiox9080659

Borowiec, K., Michalak, A., Targowska-Duda, K. (2026). Structure-Activity Relationship of Flavonol O-Methylation Revealed by In Vitro, In Silico and Zebrafish Neurodegeneration Models. International journal of molecular sciences, 27(11), 4988. https://doi.org/10.3390/ijms27114988

Dewanjee, S., Bhattacharya, H., Bhattacharyya, C., Chakraborty, P., Fleishman, J., Alexiou, A., Papadakis, M., Jha, S. K. (2024). Nrf2/Keap1/ARE regulation by plant secondary metabolites: a new horizon in brain tumor management. Cell communication and signaling: CCS, 22(1), 497. https://doi.org/10.1186/s12964-024-01878-2

Xue, S., Tan, W., Mao, S., Pan, H., Ye, X., Donlao, N., Tian, J. (2025). Polyphenol-Based Functional Materials: Structural Insights, Composite Strategies, and Biomedical Applications. Advanced Science, 12(39): e08924. https://doi.org/10.1002/advs.202508924

Dhaliwal, J. S., Moshawih, S., Goh, K. W., Loy, M. J., Hossain, M. S., Hermansyah, A., Kotra, V., Kifli, N., Goh, H. P., Dhaliwal, S. K. S., Yassin, H., Ming, L. C. (2022). Pharmacotherapeutics applications and chemistry of open-chain C6-C3-C6 chalcone derivatives in oxidative stress. Molecules, 27(20), 7062. https://doi.org/10.3390/molecules27207062

Razak, A.M., Tan, J.K., Mohd Said, M., Makpol, S. (2023). Modulating Effects of Zingiberaceae Phenolic Compounds on Neurotrophic Factors and Their Potential as Neuroprotectants in Brain Disorders and Age-Associated Neurodegenerative Disorders: A Review. Nutrients, 15(11), 2564. https://doi.org/10.3390/nu15112564

Zeng, C., Zhao, J., Chen, H., Xin, C., Wang, B., Yu, M., Wei, J. (2023). Traditional use, germplasm identification, phytochemistry, pharmacology of Bupleuri Radix: a review. Medicinal Plant Biology, 2(1), 18. https://doi.org/10.48130/mpb-2023-0018

Zammel, N., Saeed, M., Bouali, N., Elkahoui, S., Alam, J.M., Rebai, T., Kausar, M.A., Adnan, M., Siddiqui, A.J., Badraoui, R. (2021). Antioxidant and Anti-Inflammatory Effects of Zingiber officinale roscoe and Allium subhirsutum: In Silico, Biochemical and Histological Study. Foods, 10(6), 1383. https://doi.org/10.3390/foods10061383

Sharma, R., Majee, C., Mazumder, R., Padhi, S., Khan, F., Pal, R.S. (2024). Insight into the Regulation of Nrf2/Keap 1 Pathway by Flavonoids as an Approach for Treatment of Liver Diseases: A Review. Indian Journal of Pharmaceutical Education and Research, 58(1s), s40–s57. https://doi.org/10.5530/ijper.58.1s.4

Guo, J., Duan, X., Xu, H., Xu, Z., Fernie, A.R., Zhang, Y. (2026). Beyond a simple oxidation reaction: the complex molecular network regulating fruit and vegetable browning. Horticulture Research, 13(6):uhag060. https://doi.org/10.1093/hr/uhag060

Alqudah, S., Claesen, J. (2024). Mechanisms of gut bacterial metabolism of dietary polyphenols into bioactive compounds. Gut microbes, 16(1), 2426614. https://doi.org/10.1080/19490976.2024.2426614

Ciupei, D., Colişar, A., Leopold, L., Stănilă, A., Diaconeasa, Z.M. (2024). Polyphenols: From Classification to Therapeutic Potential and Bioavailability. Foods, 13(24), 4131. https://doi.org/10.3390/foods13244131

Parvin, N., Aslam, M., Joo, S.W., Mandal, T.K. (2025). Nano-Phytomedicine: Harnessing Plant-Derived Phytochemicals in Nanocarriers for Targeted Human Health Applications. Molecules, 30(15), 3177. https://doi.org/10.3390/molecules30153177

Singh, D.D., Yadav, D.K., Shin, D. (2026). Phytochemicals and REDOX Modulation: Molecular Mechanisms, Clinical Relevance, and Therapeutic Perspectives. Antioxidants (Basel, Switzerland), 15(2), 272. https://doi.org/10.3390/antiox15020272

Wei, Y.-S., Liu, K.-L., Feng, K., Wang, Y. (2025). Active Targeting Strategies for Improving the Bioavailability of Curcumin: A Systematic Review. Foods, 14(19), 3331. https://doi.org/10.3390/foods14193331

Alali, M.A., Shori, A.B. (2026). Understanding the human gut microbiome: from composition to disease association. Frontiers in Microbiomes 5:1717288. https://doi.org/10.3389/frmbi.2026.1717288

Jancova, P., Anzenbacher, P., & Anzenbacherova, E. (2010). Phase II drug metabolizing enzymes. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 154(2), 103–116. https://doi.org/10.5507/bp.2010.017

Zahir, A., Dhillon, G.K., Akhter, S., Bora, P. (2026). A comprehensive review on bioaccessibility and bioavailability of legume-derived polyphenols. Food Production, Processing and Nutrition 8, 26. https://doi.org/10.1186/s43014-026-00371-2

Aatif, M. (2023). Current Understanding of Polyphenols to Enhance Bioavailability for Better Therapies. Biomedicines, 11(7), 2078. https://doi.org/10.3390/biomedicines11072078

Li, H., Gao, J., Peng, W., Sun, X., Qi, W., Wang, Y. (2025). Dietary Polyphenols-Gut Microbiota Interactions: Intervention Strategies and Metabolic Regulation for Intestinal Diseases. Biology, 14(12), 1705. https://doi.org/10.3390/biology14121705

Cortés-Martín, A., Selma, M. V., Tomás-Barberán, F. A., González-Sarrías, A., Espín, J. C. (2020). Where to Look into the Puzzle of Polyphenols and Health? The Postbiotics and Gut Microbiota Associated with Human Metabotypes. Molecular nutrition and food research, 64(9), e1900952. https://doi.org/10.1002/mnfr.201900952

Li, H., Gao, J., Peng, W., Sun, X., Qi, W., Wang, Y. (2025). Dietary Polyphenols-Gut Microbiota Interactions: Intervention Strategies and Metabolic Regulation for Intestinal Diseases. Biology, 14(12), 1705. https://doi.org/10.3390/biology14121705

Mignet, N., Seguin, J., & Chabot, G. G. (2013). Bioavailability of polyphenol liposomes: a challenge ahead. Pharmaceutics, 5(3), 457–471. https://doi.org/10.3390/pharmaceutics5030457

Choi, S.J., McClements, D.J. (2020). Nanoemulsions as delivery systems for lipophilic nutraceuticals: strategies for improving their formulation, stability, functionality and bioavailability. Food Sci Biotechnol 29, 149–168. https://doi.org/10.1007/s10068-019-00731-4

Elmowafy, M., Shalaby, K., Elkomy, M. H., Alsaidan, O. A., Gomaa, H. A. M., Abdelgawad, M. A., Mostafa, E. M. (2023). Polymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges. Polymers, 15(5), 1123. https://doi.org/10.3390/polym15051123

Wang, Z., Song, X., Sun, M., Zhang, R., Yang, L. (2025). Bench-to-bedside translation of podophyllotoxin-based nanomedicines for cancer treatment: utopias and reality?. Microstructures, 5, 2025094. https://dx.doi.org/10.20517/microstructures.2025.71

Ren, J., Yan, G., Yang, L., Kong, L., Guan, Y., Sun, H., Liu, C., Liu, L., Han, Y., Wang, X. (2025). Cancer chemoprevention: signaling pathways and strategic approaches. Sig Transduct Target Ther 10, 113 (2025). https://doi.org/10.1038/s41392-025-02167-1

Llovet, J.M., Willoughby, C.E., Singal, A.G., Greten, T.F., Heikenwälder, M., El-Serag, H.B., Finn, R.S., Friedman, S.L. (2023). Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nature reviews. Gastroenterology and hepatology, 20(8), 487–503. https://doi.org/10.1038/s41575-023-00754-7

Mathew, J., Erattil Ahammed, S.Y., Salah, G.B., Elghazaly, A., Farhana, S.A., Hussain, S.M. (2026). Herbal-derived phytochemicals in hepatocellular carcinoma: A review of molecular targets and tumor microenvironment interventions. Journal of Herbmed Pharmacology, 15(1):11-26. https://doi.org/10.34172/jhp.2026.53276

Ursic-Bedoya, J., Guiu, B. (2020). Hepatocellular carcinoma chemoprevention in chronic hepatitis B patients: all-in on statins?. Hepatobiliary surgery and nutrition, 9(5), 676–678. https://doi.org/10.21037/hbsn.2020.03.06

Yang, P., Li, X., Yang, L., Xiao, N., Ren, L., Ji, M., Yang, H. (2026). NF-κB signaling in hepatocellular carcinoma: Mechanisms of tumor progression, immune evasion, and therapeutic resistance. Translational Oncology, 67. https://doi.org/10.1016/j.tranon.2026.102760

Dewidar, B., Meyer, C., Dooley, S., Meindl-Beinker, A. N. (2019). TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. Cells, 8(11), 1419. https://doi.org/10.3390/cells8111419

Gong, J., Xie, J., Bedolla, R., Rivas, P., Chakravarthy, D., Freeman, J.W., Reddick, R., Kopetz, S., Peterson, A., Wang, H., Fischer, S.M., Kumar, A.P. (2014). Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 20(5), 1259–1273. https://doi.org/10.1158/1078-0432.CCR-13-1664

He, G., Karin, M. (2011). NF-κB and STAT3 - key players in liver inflammation and cancer. Cell research, 21(1), 159–168. https://doi.org/10.1038/cr.2010.183

Zhang, X., Zhao, Z., Wang, F., Chen, Z. (2024). Bakuchiol Induces Apoptosis in Human Hepatocellular Carcinoma Cells HepG2 via Enhancing Bcl-2/Bax/Cyc-t/Caspase-3 Signaling Pathway. International Journal of Pharmacology, 20: 862-873. https://doi.org/10.3923/ijp.2024.862.873

Singh, R., Letai, A., Sarosiek, K. (2019). Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nature reviews. Molecular cell biology, 20(3), 175–193. https://doi.org/10.1038/s41580-018-0089-8

Otto, T., Sicinski, P. (2017). Cell cycle proteins as promising targets in cancer therapy. Nature reviews. Cancer, 17(2), 93–115. https://doi.org/10.1038/nrc.2016.138

Cui, J., Shen, H.M., Lim, L.H.K. (2020). The Role of Autophagy in Liver Cancer: Crosstalk in Signaling Pathways and Potential Therapeutic Targets. Pharmaceuticals (Basel, Switzerland), 13(12), 432. https://doi.org/10.3390/ph13120432

Alharbi, M. (2026). AMPK as a Double-Edged sword in cancer: role of natural compounds in its regulation. Natural Product Research, 1–16. https://doi.org/10.1080/14786419.2026.2655945

Klionsky, D.J., Petroni, G., Amaravadi, R.K., Baehrecke, E.H., Ballabio, A., Boya, P., Bravo-San Pedro, J.M., Cadwell, K., Cecconi, F., Choi, A.M.K., Choi, M.E., Chu, C.T., Codogno, P., Colombo, M.I., Cuervo, A.M., Deretic, V., Dikic, I., Elazar, Z., Eskelinen, E. L., Fimia, G.M., … Pietrocola, F. (2021). Autophagy in major human diseases. The EMBO journal, 40(19), e108863. https://doi.org/10.15252/embj.2021108863

Patergnani, S., Missiroli, S., Morciano, G., Perrone, M., Mantovani, C.M., Anania, G., Fiorica, F., Pinton, P., Giorgi, C. (2021). Understanding the Role of Autophagy in Cancer Formation and Progression Is a Real Opportunity to Treat and Cure Human Cancers. Cancers, 13(22), 5622. https://doi.org/10.3390/cancers13225622

Tonelli, C., Chio, I. I. C., Tuveson, D. A. (2018). Transcriptional Regulation by Nrf2. Antioxidants and redox signaling, 29(17), 1727–1745. https://doi.org/10.1089/ars.2017.7342

He, F., Ru, X., Wen, T. (2020). NRF2, a Transcription Factor for Stress Response and Beyond. International journal of molecular sciences, 21(13), 4777. https://doi.org/10.3390/ijms21134777

Baird, L., Yamamoto, M. (2020). (2020). The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway. Molecular and Cellular Biology, 40(13). https://doi.org/10.1128/MCB.00099-20

Canning, P., Sorrell, F.J., Bullock, A.N. (2015). Structural basis of Keap1 interactions with Nrf2. Free radical biology and medicine, 88(Pt B), 101–107. https://doi.org/10.1016/j.freeradbiomed.2015.05.034

Tu, W., Wang, H., Li, S., Liu, Q., Sha, H. (2019). The Anti-Inflammatory and Anti-Oxidant Mechanisms of the Keap1/Nrf2/ARE Signaling Pathway in Chronic Diseases. Aging and disease, 10(3), 637–651. https://doi.org/10.14336/AD.2018.0513

Stefanson, A. L., & Bakovic, M. (2014). Dietary Regulation of Keap1/Nrf2/ARE Pathway: Focus on Plant-Derived Compounds and Trace Minerals. Nutrients, 6(9), 3777-3801. https://doi.org/10.3390/nu6093777

Suzuki, T., Takahashi, J., Yamamoto, M. (2023). Molecular Basis of the KEAP1-NRF2 Signaling Pathway. Molecules and cells, 46(3), 133–141. https://doi.org/10.14348/molcells.2023.0028

Small, D.M., Coombes, J.S., Bennett, N., Johnson, D. W., Gobe, G.C. (2012). Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton, Vic.), 17(4), 311–321. https://doi.org/10.1111/j.1440-1797.2012.01572.x

Ngo, V., Duennwald, M.L. (2022). Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease. Antioxidants (Basel, Switzerland), 11(12), 2345. https://doi.org/10.3390/antiox11122345

Soni, D., Kumar, P. (2022). GSK-3β-mediated regulation of Nrf2/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders. Pharmacological reports : PR, 74(4), 557–569. https://doi.org/10.1007/s43440-022-00390-z

Sies, H., Jones, D.P. (2020). Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nature reviews. Molecular cell biology, 21(7), 363–383. https://doi.org/10.1038/s41580-020-0230-3

Sánchez-Martín, P., Komatsu, M. (2018). p62/SQSTM1 - steering the cell through health and disease. Journal of cell science, 131(21), jcs222836. https://doi.org/10.1242/jcs.222836

Taguchi, K., Yamamoto, M. (2020). The KEAP1-NRF2 System as a Molecular Target of Cancer Treatment. Cancers, 13(1), 46. https://doi.org/10.3390/cancers13010046

Allocati, N., Masulli, M., Di Ilio, C., Federici, L. (2018). Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis, 7(1), 8. https://doi.org/10.1038/s41389-017-0025-3

Hayes, J.D., Dinkova-Kostova, A.T. (2014). The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends in biochemical sciences, 39(4), 199–218. https://doi.org/10.1016/j.tibs.2014.02.002

Ross, D., Siegel, D. (2021). The diverse functionality of NQO1 and its roles in redox control. Redox biology, 41, 101950. https://doi.org/10.1016/j.redox.2021.101950

Yuhan, L., Khaleghi Ghadiri, M., Gorji, A. (2024). Impact of NQO1 dysregulation in CNS disorders. Journal of translational medicine, 22(1), 4. https://doi.org/10.1186/s12967-023-04802-3

Ryter S.W. (2019). Heme oxygenase-1/carbon monoxide as modulators of autophagy and inflammation. Archives of biochemistry and biophysics, 678, 108186. https://doi.org/10.1016/j.abb.2019.108186

Medina, M.V., Sapochnik, D., Garcia Solá, M., Coso, O. (2020). Regulation of the Expression of Heme Oxygenase-1: Signal Transduction, Gene Promoter Activation, and Beyond. Antioxidants and redox signaling, 32(14), 1033–1044. https://doi.org/10.1089/ars.2019.7991

Lu, S.C. (2013). Glutathione synthesis. Biochimica et biophysica acta, 1830(5), 3143–3153. https://doi.org/10.1016/j.bbagen.2012.09.008

Forman, H.J., Zhang, H. (2021). Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nature reviews. Drug discovery, 20(9), 689–709. https://doi.org/10.1038/s41573-021-00233-1

Ursini, F., Maiorino, M. (2020). Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free radical biology and medicine, 152, 175–185. https://doi.org/10.1016/j.freeradbiomed.2020.02.027

Koppula, P., Zhang, Y., Shi, J., Li, W., Gan, B. (2017). The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. The Journal of biological chemistry, 292(34), 14240–14249. https://doi.org/10.1074/jbc.M117.798405

Aoyama, K., Nakaki, T. (2015). Glutathione in Cellular Redox Homeostasis: Association with the Excitatory Amino Acid Carrier 1 (EAAC1). Molecules (Basel, Switzerland), 20(5), 8742–8758. https://doi.org/10.3390/molecules20058742

Couto, N., Wood, J., Barber, J. (2016). The role of glutathione reductase and related enzymes on cellular redox homoeostasis network. Free radical biology and medicine, 95, 27–42. https://doi.org/10.1016/j.freeradbiomed.2016.02.028

Esteras, N., Abramov, A.Y. (2022). Nrf2 as a regulator of mitochondrial function: Energy metabolism and beyond. Free radical biology and medicine, 189, 136–153. https://doi.org/10.1016/j.freeradbiomed.2022.07.013

Younus H. (2018). Therapeutic potentials of superoxide dismutase. International journal of health sciences, 12(3), 88–93.

Mahmoud, S., Moselhy, W., Abou El-Khashab, L., Seufi, A.M. (2018). Identification and Molecular Characterisation of a Novel Manganese Superoxide Dismutase Gene from Flesh Fly Larvae, Sarcophaga argyrostoma (Diptera: Sarcophagidae). African Entomology, 26(2): 448-457. https://doi.org/10.4001/003.026.0448

Calderon, P., Glorieux, C. (2017). Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach. Biological Chemistry, 398(10), 1095–1108. https://doi.org/10.1515/hsz-2017-0131

Paonessa, J.D., Ding, Y., Randall, K.L., Munday, R., Argoti, D., Vouros, P., Zhang, Y. (2011). Identification of an unintended consequence of Nrf2-directed cytoprotection against a key tobacco carcinogen plus a counteracting chemopreventive intervention. Cancer research, 71(11), 3904–3911. https://doi.org/10.1158/0008-5472.CAN-11-0396

Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., Cuadrado, A. (2019). Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxidative medicine and cellular longevity, 2019, 9372182. https://doi.org/10.1155/2019/9372182

Townsend, D.M., Tew, K.D. (2003). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22(47), 7369–7375. https://doi.org/10.1038/sj.onc.1206940

Bai, X., Chen, Y., Hou, X., Huang, M., Jin, J. (2016). Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug metabolism reviews, 48(4), 541–567. https://doi.org/10.1080/03602532.2016.1197239

Cooper, A.J., Krasnikov, B.F., Niatsetskaya, Z.V., Pinto, J.T., Callery, P.S., Villar, M.T., Artigues, A., Bruschi, S.A. (2011). Cysteine S-conjugate β-lyases: important roles in the metabolism of naturally occurring sulfur and selenium-containing compounds, xenobiotics and anticancer agents. Amino acids, 41(1), 7–27. https://doi.org/10.1007/s00726-010-0552-0

Rojo de la Vega, M., Chapman, E., Zhang, D.D. (2018). NRF2 and the Hallmarks of Cancer. Cancer cell, 34(1), 21–43. https://doi.org/10.1016/j.ccell.2018.03.022

Ngo, H.K.C., Le, H., Surh, Y.J. (2023). Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment. Journal of cancer prevention, 28(4), 131–142. https://doi.org/10.15430/JCP.2023.28.4.131

Gonzalez-Donquiles, C., Alonso-Molero, J., Fernandez-Villa, T., Vilorio-Marqués, L., Molina, A.J., Martín, V. (2017). The NRF2 transcription factor plays a dual role in colorectal cancer: A systematic review. PLoS ONE 12(5): e0177549. https://doi.org/10.1371/journal.pone.0177549

Oskomić, M., Tomić, A., Barbarić, L., Matić, A., Kindl, D.C., Matovina, M. (2025). KEAP1-NRF2 Interaction in Cancer: Competitive Interactors and Their Role in Carcinogenesis. Cancers, 17(3), 447. https://doi.org/10.3390/cancers17030447

Telkoparan-Akillilar, P., Panieri, E., Cevik, D., Suzen, S., Saso, L. (2021). Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer. Molecules, 26(5), 1417. https://doi.org/10.3390/molecules26051417

Sharifi-Rad, J., Seidel, V., Izabela, M., Monserrat-Mequida, M., Sureda, A., Ormazabal, V., Zuniga, F.A., Mangalpady, S.S., Pezzani, R., Ydyrys, A., Tussupbekova, G., Martorell, M., Calina, D., Cho, W.C. (2023). Phenolic compounds as Nrf2 inhibitors: potential applications in cancer therapy. Cell communication and signaling : CCS, 21(1), 89. https://doi.org/10.1186/s12964-023-01109-0

Zhang, J., Xu, H. X., Zhu, J. Q., Dou, Y. X., Xian, Y.F., Lin, Z.X. (2023). Natural Nrf2 inhibitors: A review of their potential for cancer treatment. International Journal of Biological Sciences, 19(10), 3029–3041. https://doi.org/10.7150/ijbs.82401

Bambach, N.E., Ricarte-Filho, J.C., Reichenberger, E.R., Hernandez-Padilla, C., Hinkle, K., Isaza, A., Bauer, A.J., Franco, A.T. (2026). KEAP1 mutations activate the NRF2 pathway to drive cell growth and migration, and attenuate drug response in thyroid cancer. Frontiers in Oncology, 15:1685379. https://doi.org/10.3389/fonc.2025.1685379

Bruneska Gondim Martins, D., Cristina de Aguiar, A., Maria de Araújo Barbosa, F., Moreira Leitão, G. (2024). The dual role of NRF2 transcription factor in female cancer. IntechOpen, Article 1005041. https://doi.org/10.5772/intechopen.1005041

Yang, Y., Tian, Z., Guo, R., Ren, F. (2020). Nrf2 inhibitor, brusatol in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive cancers by inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 pathways. Oxidative Medicine and Cellular Longevity, 2020, 9867595. https://doi.org/10.1155/2020/9867595

Baird, L., Zhang, L., Hidaka, T., Xi, L., Wang, K., Tateno, K., Iso, T., Suzuki, T., Kumada, K., Katsuoka, F., Kinoshita, K., Yamamoto, M. (2025). Systemic activation of NRF2 contributes to the therapeutic efficacy of clinically-approved KRAS-G12C anti-cancer drugs. British journal of cancer, 133(9), 1377–1390. https://doi.org/10.1038/s41416-025-03162-7

Wang, Y., Zhang, Z., Jiao, W., Wang, Y., Wang, X., Zhao, Y., Fan, X., Tian, L., Li, X., & Mi, J. (2022). Ferroptosis and its role in skeletal muscle diseases. Frontiers in molecular biosciences, 9, 1051866. https://doi.org/10.3389/fmolb.2022.1051866

Gelerstein-Claro, S., Méndez-Valdés, G., Rodrigo, R. (2025). Effects of the Pharmacological Modulation of NRF2 in Cancer Progression. Medicina, 61(12), 2224. https://doi.org/10.3390/medicina61122224

Demirezen, A., Erbaş, O. (2024). Balancing Act: NRF2's contradictory roles in cancer progression and therapy. Demiroglu Journal of Medical Sciences, 10(3):123-128. https://doi.org/10.5606/fng. btd.2024.160

Zhang, J., Pearson, A.J., Sabherwal, N., Telfer, B.A., Ali, N., Kan, K., Xu, Q., Zhang, W., Chen, F., Li, S., Wang, J., Gray, N.S., Risa-Ebrí, B., Finegan, K.G., Cross, M.J., Giurisato, E., Whitmarsh, A.J., Tournier, C. (2021). Epigenetic silencing and somatic alterations of KEAP1/NRF2 axis in therapy-resistant solid tumors. Cancer Research Communications, 1(4), 210–224. https://doi.org/10.1158/2767-9764.CRC-21-0089

Tang, Y., Chuang, Y-J., Chang, H-H., Juang, S-H., Yen, G-C., Chang, J-Y., Kuo, C-C. (2023). How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy. Journal of Food and Drug Analysis, 31(3), 2. https://doi.org/10.38212/2224-6614.3463

Nilo, D. di Lorenzo, G., La Montagna, M., Nevola, R., Marrone, A., Sasso, F.C., Caturano, A. (2026). Gut Microbiota, Oxidative Stress, and Inflammation: Pathophysiological Crosstalk in MASLD, MASH, and Hepatocellular Carcinoma. BIOCELL, 50(2), 112–125. https://doi.org/10.32604/biocell.2026.081324

Lee, D.H., Kim, D.Y., Joung, H., Kim, H., Jeon, Y., Lee, S., Shin, C.H., Lee, Y.S., Bang, J.Y., Lee, E.J., Cha, S.Y., Bae, S.H., Lee, H.W. (2026). Probiotic-driven gut-liver redox crosstalk modulates hepatic Nrf2 signaling pathway and attenuates metabolic dysfunction-associated steatohepatitis. Free radical biology and medicine, 253, 527–543. https://doi.org/10.1016/j.freeradbiomed.2026.05.338

Ma, J., Ma, Y., Wan, X., Li, J., Zhang, Y., Liu, J., Gao, Y. (2025). Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: an integrative perspective from molecular pathways to clinical challenges. Front. Endocrinology, 16:1639064. https://doi.org/10.3389/fendo.2025.1639064

Shin, S., Kim, J., Lee, J., Kim, J., Oh, C-M. (2023). Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Journal of Obesity and Metabolic Syndrome, 32(4): 289-302. https://doi.org/10.7570/jomes23054

Akl, M.G., Li, L., Widenmaier, S.B. (2024). Protective Effects of Hepatocyte Stress Defenders, Nrf1 and Nrf2, against MASLD Progression. International journal of molecular sciences, 25(15), 8046. https://doi.org/10.3390/ijms25158046

Nakamura, T., Masuda, A., Nakano, D., Amano, K., Sano, T., Nakano, M., Kawaguchi, T. (2025). Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma. Cells, 14(6), 428. https://doi.org/10.3390/cells14060428

Setiawati, L., Liem, I.K., Husna, F.A. (2023). Nuclear Factor Erythroid 2-Related Factor 2 Versus Reactive Oxygen Species: Potential Therapeutic Approach on Fighting Liver Fibrosis. Open Access Macedonian Journal of Medical Sciences, 11(F), 115–123. https://doi.org/10.3889/oamjms.2023.11334

Kudo, J., Hirono, H., Ohkoshi, S. (2025). Low-frequency, mild-gradient chronic intermittent hypoxia still induces liver fibrogenesis in mice on a high-fat diet. Biochemical and Biophysical Research Communications, 761, 151744. https://doi.org/10.1016/j.bbrc.2025.151744

Messex, J.K., Byrd, C.J., Liou, G.-Y. (2020). Signaling of Macrophages that Contours the Tumor Microenvironment for Promoting Cancer Development. Cells, 9(4), 919. https://doi.org/10.3390/cells9040919

Zou, H., Wang, S., Huang, C., Dooley, S., Meindl-Beinker, N.M. (2026). Transforming Growth Factor-β Signaling in Alcohol-Associated Liver Disease. The American Journal of Pathology, 196, 50-67. https://doi.org/10.1016/j.ajpath.2025.09.017

Arteel G.E. (2024). Hepatic Extracellular Matrix and Its Role in the Regulation of Liver Phenotype. Seminars in liver disease, 44(3), 343–355. https://doi.org/10.1055/a-2404-7973

Feng, R., Morine, Y., Ikemoto, T., Imura, S., Iwahashi, S., Saito, Y., Shimada, M. (2018). Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction. Cell communication and signaling : CCS, 16(1), 54. https://doi.org/10.1186/s12964-018-0262-x

Chen, C., Wang, Z., Ding, Y., Qin, Y. (2023). Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Frontiers in immunology, 14, 1133308. https://doi.org/10.3389/fimmu.2023.1133308

Cha, J.Y., Kim, D.H., Chun, K.H. (2018). The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Laboratory animal research, 34(4), 133–139. https://doi.org/10.5625/lar.2018.34.4.133

Du, J.Y., Zhang, C.T., Li, T., Li, Y.P. (2024). Targeting hypoxia and angiogenesis in hepatocellular carcinoma: New insights and therapeutic strategies. World journal of hepatology, 16(12), 1371–1376. https://doi.org/10.4254/wjh.v16.i12.1371

Li, S.Q., Yang, Y., Ye, L.S. (2022). Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World journal of gastroenterology, 28(42), 6034–6044. https://doi.org/10.3748/wjg.v28.i42.6034

Clifford, T., Acton, J.P., Cocksedge, S.P., Davies, K.A.B., Bailey, S.J. (2021). The effect of dietary phytochemicals on nuclear factor erythroid 2-related factor 2 (Nrf2) activation: a systematic review of human intervention trials. Molecular biology reports, 48(2), 1745–1761. https://doi.org/10.1007/s11033-020-06041-x

Singh, D. D., Yadav, D. K., & Shin, D. (2026). Phytochemicals and REDOX Modulation: Molecular Mechanisms, Clinical Relevance, and Therapeutic Perspectives. Antioxidants, 15(2), 272. https://doi.org/10.3390/antiox15020272

Papadopoulou, S.K., Poulios, E., Pritsa, A., Psara, E., Migdanis, A., Giaginis, C. (2026). Natural Products as Promising Pharmacological Agents Against Cancer: A Holistic Overview of Their Anti-Cancer Mechanisms of Action of the Last Five Years. Pharmaceuticals, 19(6), 910. https://doi.org/10.3390/ph19060910

Fan, Q., Wang, X., Zhang, H., Chang, Z., Wang, N., Fan, S., Li, Z., Xu, X., Zhao, C., Li, X. (2026). Multi-Dimensional Mechanisms and Druggability Optimization Strategies of Active Ingredients from Traditional Chinese Medicine in the Treatment of Ulcerative Colitis. Pharmaceuticals, 19(7), 977. https://doi.org/10.3390/ph19070977

Yao, Y.-Y., Ye, Y., Xiong, K., Mao, S.-C., Jiang, J.-W., Chen, Y.-Q., Li, X., Liu, H.-B., Liu, L.-C., Cai, B., Song, S. (2026). Current Progress and Future Directions of Enzyme Technology in Food Nutrition: A Comprehensive Review of Processing, Nutrition, and Functional Innovation. Foods, 15(2), 402. https://doi.org/10.3390/foods15020402

Dai, Y., Chen, Y. (2025). Targeting persistently activated inflammatory microenvironment to promote chronic wound healing. Frontiers in immunology, 16, 1708358. https://doi.org/10.3389/fimmu.2025.1708358

Rigillo, G., Blom, J.M.C., Cocchi, A., Martinucci, V., Favaro, F., Baini, G., Cappellucci, G., Tascedda, F., Biagi, M. (2025). Medicinal Plants for Child Mental Health: Clinical Insights, Active Compounds, and Perspectives for Rational Use. Children, 12(9), 1142. https://doi.org/10.3390/children12091142

Yang, D., Park, S.Y., Park, Y.S., Eun, H., Lee, S.Y. (2020). Metabolic Engineering of Escherichia coli for Natural Product Biosynthesis. Trends in biotechnology, 38(7), 745–765. https://doi.org/10.1016/j.tibtech.2019.11.007

Hanko, E.K.R., Robinson, C.J., Bhanot, S., Jervis, A.J., Scrutton, N.S. (2024). Engineering an Escherichia coli strain for enhanced production of flavonoids derived from pinocembrin. Microbial cell factories, 23(1), 312. https://doi.org/10.1186/s12934-024-02582-z

Sun, M.L., Zou, Z., Lin, L., Ledesma-Amaro, R., Wang, K., Ji, X.J. (2024). Systematic metabolic engineering of Yarrowia lipolytica for efficient production of phytohormone abscisic acid. Synthetic and systems biotechnology, 10(1), 165–173. https://doi.org/10.1016/j.synbio.2024.10.004

Chen, R., Yang, S., Zhang, L., Zhou, Y.J. (2020). Advanced Strategies for Production of Natural Products in Yeast. iScience, 23(3), 100879. https://doi.org/10.1016/j.isci.2020.100879

Fontanella, F., D'Alessandro, T., Nardone, E., De Stefano, C., Vicidomini, C., Roviello, G.N. (2026). Artificial Intelligence for Natural Products Drug Discovery in Neurodegenerative Therapies: A Review. Biomolecules, 16(1), 129. https://doi.org/10.3390/biom16010129

Zhang, R., Li, X., Zhang, X., Qin, H., Xiao, W. (2021). Machine learning approaches for elucidating the biological effects of natural products. Natural product reports, 38(2), 346–361. https://doi.org/10.1039/d0np00043d

Fahrmann, J.F., Tanaka, I., Irajizad, E., Mao, X., Dennison, J.B., Murage, E., Casabar, J., Mayo, J., Peng, Q., Celiktas, M., Vykoukal, J.V., Park, S., Taguchi, A., Delgado, O., Tripathi, S.C., Katayama, H., Soto, L.M.S., Rodriguez-Canales, J., Behrens, C., ... Ostrin, E.J. (2022). Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma. Cancers, 14(10), 2543. https://doi.org/10.3390/cancers14102543

Baird, L., Yamamoto, M. (2020). The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway. Molecular and cellular biology, 40(13), e00099-20. https://doi.org/10.1128/MCB.00099-20

Rojo de la Vega, M., Chapman, E., Zhang, D.D. (2018). NRF2 and the Hallmarks of Cancer. Cancer cell, 34(1), 21–43. https://doi.org/10.1016/j.ccell.2018.03.022

Kawabe, M., Yang, S., Bolanos, L.G., Takamatsu, S., Flores, S., Castro, P.D., Tsai, T.Y., Nishikawa-Kaga, A., Frederick, M.J., Sandulache, V., Kadara, H., Myers, J.N., Osman, A.A. (2025). Targeted suppression of SPP1 inhibits tumor invasion and metastasis in NRF2 hyperactivated cisplatin resistant HNSCC. bioRxiv : the preprint server for biology, 2025.05.28.656679. https://doi.org/10.1101/2025.05.28.656679

Kitamura, H., & Motohashi, H. (2018). NRF2 addiction in cancer cells. Cancer science, 109(4), 900–911. https://doi.org/10.1111/cas.13537

He, F., Ru, X., Wen, T. (2020). NRF2, a Transcription Factor for Stress Response and Beyond. International journal of molecular sciences, 21(13), 4777. https://doi.org/10.3390/ijms21134777

Systemic Preventive and Detoxifying Efficacy of Phenolics and Flavonoids Against Carcinogenesis: A Comprehensive Analysis of the Transition from Cellular Protection to Systemic Metabolic Resilience